Actively Recruiting
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
Led by Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Updated on 2025-09-30
64
Participants Needed
1
Research Sites
64 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups
CONDITIONS
Official Title
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy adult subjects
- Signed informed consent
You will not qualify if you...
- History or presence of any clinically significant organ system disease that could interfere with the study or safety
- Prior use of drug targeting TNF-like cytokine 1A
- History of malignant tumor
- Positive results for Hepatitis B surface antigen, anti Hepatitis C antibody, or human immunodeficiency virus
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Friendship hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100050
Actively Recruiting
Research Team
N
Nian
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here